Posted by Michael Wonder on 04 Aug 2018
Patents and negotiations: three new reports dig in on drug prices
2 August 2018 - Drug prices. Rebates. Middlemen. Gouging.
Buzzwords are flying and not only in the pharmacy, but on Capitol Hill, in C-suite executives’ offices and at the White House. However, the story is more complicated than just: Drug prices are too high and need to be lower.
As part of efforts to elucidate how much drugs cost and why they cost so much, three new reports released this week take a crack at explaining the details of how the government negotiates drug prices, how patents can extend the monopolies on best-selling drugs and biologics, and who exactly is reaping the benefits of those high prices.
